Drug-vs-Drug Verdicts: GLP-1 & Weight Loss Comparisons
Head-to-head verdicts on the most-searched GLP-1 drug pairings. Every comparison cell cites an FDA label (DailyMed), a peer-reviewed trial, or a current manufacturer price page.
Looking for provider-vs-provider comparisons or full provider rankings?
All drug-vs-drug verdicts
Wegovy vs Zepbound
semaglutide · tirzepatide
Zepbound delivered 20.9% TBWL in SURMOUNT-1 vs Wegovy's 14.9% in STEP-1 — and SURMOUNT-5 head-to-head confirmed Zepbound −20.2% vs Wegovy −13.7% over 72 weeks.
Last verified 2026-05-27
Ozempic vs Mounjaro
semaglutide · tirzepatide
SURPASS-2 head-to-head: Mounjaro 15mg dropped weight 11.2 kg vs Ozempic 1mg's 5.7 kg at 40 weeks. Ozempic wins on proven CV outcomes (SUSTAIN-6 MACE -26%).
Last verified 2026-05-27
Semaglutide vs Tirzepatide
semaglutide · tirzepatide
SURMOUNT-5 head-to-head: tirzepatide -20.2% body weight vs semaglutide -13.7% at 72 weeks. Semaglutide wins on CV outcomes (SELECT -20% MACE). Compare mechanisms and access.
Last verified 2026-05-27
Rybelsus vs Ozempic
semaglutide (oral) · semaglutide (subcutaneous)
Rybelsus is oral semaglutide (3/7/14 mg daily); Ozempic is injectable semaglutide (0.25-2 mg weekly). Same molecule — oral bioavailability ~1% means injection delivers more drug.
Last verified 2026-05-27
Mounjaro vs Zepbound
tirzepatide · tirzepatide
Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly — Mounjaro is FDA-labeled for type 2 diabetes; Zepbound for obesity and obstructive sleep apnea.
Last verified 2026-05-27
Foundayo vs Rybelsus
orforglipron · semaglutide (oral)
Foundayo (orforglipron) is the first non-peptide oral GLP-1 — no food restriction, 11-12% weight loss in ATTAIN-1. Rybelsus is oral semaglutide — strict 30-min fast, T2D-only.
Last verified 2026-05-27
Mounjaro vs Wegovy
tirzepatide · semaglutide
Mounjaro is FDA-labeled for type 2 diabetes only; Wegovy is FDA-labeled for obesity + CV risk reduction. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7%.
Last verified 2026-05-27
Ozempic vs Zepbound
semaglutide · tirzepatide
Ozempic is labeled for type 2 diabetes; Zepbound for obesity and OSA. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.
Last verified 2026-05-27